Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

21.04CHF
22 May 2018
Change (% chg)

CHF-0.12 (-0.57%)
Prev Close
CHF21.16
Open
CHF21.14
Day's High
CHF21.44
Day's Low
CHF20.70
Volume
151,887
Avg. Vol
354,878
52-wk High
CHF30.70
52-wk Low
CHF10.00

Select another date:

Wed, May 16 2018

BRIEF-Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease

* IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Idorsia: US GAAP Oper Loss Of CHF 74 Mln In Q1 2018

* IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2018

BRIEF-Idorsia FY US GAAP Loss Of CHF 8 Million

* US GAAP OPERATING RESULTS 2017: YTD LOSS OF CHF 8 MILLION; Q4 PROFIT OF CHF 71 MILLION

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million (171 million pounds)from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

Idorsia to get $230 mln from J&J in latest hypertension deal

ZURICH, Dec 4 Idorsia, the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J), will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

BRIEF-Idorsia Announces Collaboration With Janssen Biotech On Aprocitentan

* IDORSIA ANNOUNCES COLLABORATION WITH JANSSEN BIOTECH ON APROCITENTAN (ACT-132577)

Select another date: